1
|
Tambat N, Mulani SK, Ahmad A, Shaikh SB, Ahmed K. Pyrazine Derivatives—Versatile Scaffold. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2022. [DOI: 10.1134/s1068162022050259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
2
|
Bouz G, Bouz S, Janďourek O, Konečná K, Bárta P, Vinšová J, Doležal M, Zitko J. Synthesis, Biological Evaluation, and In Silico Modeling of N-Substituted Quinoxaline-2-Carboxamides. Pharmaceuticals (Basel) 2021; 14:ph14080768. [PMID: 34451864 PMCID: PMC8399443 DOI: 10.3390/ph14080768] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 07/29/2021] [Accepted: 08/02/2021] [Indexed: 11/29/2022] Open
Abstract
Despite the established treatment regimens, tuberculosis remains an alarming threat to public health according to WHO. Novel agents are needed to overcome the increasing rate of resistance and perhaps achieve eradication. As part of our long-term research on pyrazine derived compounds, we prepared a series of their ortho fused derivatives, N-phenyl- and N-benzyl quinoxaline-2-carboxamides, and evaluated their in vitro antimycobacterial activity. In vitro activity against Mycobacterium tuberculosis H37Ra (represented by minimum inhibitory concentration, MIC) ranged between 3.91–500 µg/mL, with most compounds having moderate to good activities (MIC < 15.625 µg/mL). The majority of the active compounds belonged to the N-benzyl group. In addition to antimycobacterial activity assessment, final compounds were screened for their in vitro cytotoxicity. N-(naphthalen-1-ylmethyl)quinoxaline-2-carboxamide (compound 29) was identified as a potential antineoplastic agent with selective cytotoxicity against hepatic (HepG2), ovarian (SK-OV-3), and prostate (PC-3) cancer cells lines. Molecular docking showed that human DNA topoisomerase and vascular endothelial growth factor receptor could be potential targets for 29.
Collapse
|
3
|
Singh R, Ahmad Ganaie S, Singh A, Chaudhary A. Carbon-SO 3H catalyzed expedient synthesis of new spiro-[indeno[1,2- b]quinoxaline-[11,2′]-thiazolidine]-4′-ones as biologically important scaffold. SYNTHETIC COMMUN 2019. [DOI: 10.1080/00397911.2018.1542003] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Ruby Singh
- Department of Chemistry, School of Basic Sciences, Jaipur National University , Jaipur , Rajasthan , India
| | - Shakeel Ahmad Ganaie
- Department of Chemistry, School of Basic Sciences, Jaipur National University , Jaipur , Rajasthan , India
| | - Aakash Singh
- Department of Chemistry, School of Basic Sciences, Jaipur National University , Jaipur , Rajasthan , India
| | - Archana Chaudhary
- Discipline of Chemistry, School of Basic Sciences, Indian Institute of Technology Indore , Indore , India
| |
Collapse
|
4
|
Jang JW, Cho NC, Min SJ, Cho YS, Park KD, Seo SH, No KT, Pae AN. Novel Scaffold Identification of mGlu1 Receptor Negative Allosteric Modulators Using a Hierarchical Virtual Screening Approach. Chem Biol Drug Des 2015; 87:239-56. [DOI: 10.1111/cbdd.12654] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 07/15/2015] [Accepted: 08/18/2015] [Indexed: 11/28/2022]
Affiliation(s)
- Jae Wan Jang
- Center for Neuro-Medicine; Brain Science Institute; Korea Institute of Science and Technology (KIST); Hwarangno 14-gil 5 Seongbuk-gu, Seoul 136-791 Korea
- Department of Biological Chemistry; School of Science; Korea University of Science and Technology; 52 Eoeun dong Yuseong-gu, Daejeon 305-333 Korea
| | - Nam-Chul Cho
- Center for Neuro-Medicine; Brain Science Institute; Korea Institute of Science and Technology (KIST); Hwarangno 14-gil 5 Seongbuk-gu, Seoul 136-791 Korea
- Department of Biotechnology; Yonsei University; Seodaemun-gu, Seoul 120-749 Korea
| | - Sun-Joon Min
- Department of Applied Chemistry; Hanyang University; Ansan, Gyeonggi-do 15588 Korea
| | - Yong Seo Cho
- Center for Neuro-Medicine; Brain Science Institute; Korea Institute of Science and Technology (KIST); Hwarangno 14-gil 5 Seongbuk-gu, Seoul 136-791 Korea
- Department of Biological Chemistry; School of Science; Korea University of Science and Technology; 52 Eoeun dong Yuseong-gu, Daejeon 305-333 Korea
| | - Ki Duk Park
- Center for Neuro-Medicine; Brain Science Institute; Korea Institute of Science and Technology (KIST); Hwarangno 14-gil 5 Seongbuk-gu, Seoul 136-791 Korea
- Department of Biological Chemistry; School of Science; Korea University of Science and Technology; 52 Eoeun dong Yuseong-gu, Daejeon 305-333 Korea
| | - Seon Hee Seo
- Center for Neuro-Medicine; Brain Science Institute; Korea Institute of Science and Technology (KIST); Hwarangno 14-gil 5 Seongbuk-gu, Seoul 136-791 Korea
| | - Kyoung Tai No
- Department of Biotechnology; Yonsei University; Seodaemun-gu, Seoul 120-749 Korea
| | - Ae Nim Pae
- Center for Neuro-Medicine; Brain Science Institute; Korea Institute of Science and Technology (KIST); Hwarangno 14-gil 5 Seongbuk-gu, Seoul 136-791 Korea
- Department of Biological Chemistry; School of Science; Korea University of Science and Technology; 52 Eoeun dong Yuseong-gu, Daejeon 305-333 Korea
| |
Collapse
|
5
|
Kim Y, Kim J, Kim S, Ki Y, Seo SH, Tae J, Ko MK, Jang HS, Lim EJ, Song C, Cho Y, Koh HY, Chong Y, Choo IH, Keum G, Min SJ, Choo H. Novel thienopyrimidinones as mGluR1 antagonists. Eur J Med Chem 2014; 85:629-37. [DOI: 10.1016/j.ejmech.2014.08.027] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Revised: 08/06/2014] [Accepted: 08/07/2014] [Indexed: 11/24/2022]
|
6
|
Cho HP, Engers DW, Venable DF, Niswender CM, Lindsley CW, Conn PJ, Emmitte KA, Rodriguez AL. A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors. ACS Chem Neurosci 2014; 5:597-610. [PMID: 24798819 DOI: 10.1021/cn5000343] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Recent progress in the discovery of mGlu₁ allosteric modulators has suggested the modulation of mGlu₁ could offer possible treatment for a number of central nervous system disorders; however, the available chemotypes are inadequate to fully investigate the therapeutic potential of mGlu₁ modulation. To address this issue, we used a fluorescence-based high-throughput screening assay to screen an allosteric modulator-biased library of compounds to generate structurally diverse mGlu₁ negative allosteric modulator hits for chemical optimization. Herein, we describe the discovery and characterization of a novel mGlu₁ chemotype. This series of succinimide negative allosteric modulators, exemplified by VU0410425, exhibited potent inhibitory activity at rat mGlu₁ but was, surprisingly, inactive at human mGlu₁. VU0410425 and a set of chemically diverse mGlu₁ negative allosteric modulators previously reported in the literature were utilized to examine this species disconnect between rat and human mGlu₁ activity. Mutation of the key transmembrane domain residue 757 and functional screening of VU0410425 and the literature compounds suggests that amino acid 757 plays a role in the activity of these compounds, but the contribution of the residue is scaffold specific, ranging from critical to minor. The operational model of allosterism was used to estimate the binding affinities of each compound to compare to functional data. This novel series of mGlu₁ negative allosteric modulators provides valuable insight into the pharmacology underlying the disconnect between rat and human mGlu₁ activity, an issue that must be understood to progress the therapeutic potential of allosteric modulators of mGlu₁.
Collapse
Affiliation(s)
| | | | | | | | - Craig W. Lindsley
- Department
of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States
| | | | - Kyle A. Emmitte
- Department
of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States
| | | |
Collapse
|
7
|
3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity. Bioorg Med Chem Lett 2012; 22:2514-7. [DOI: 10.1016/j.bmcl.2012.02.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2012] [Revised: 01/31/2012] [Accepted: 02/01/2012] [Indexed: 11/17/2022]
|
8
|
Owen DR. Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu₁). ACS Chem Neurosci 2011; 2:394-401. [PMID: 22860168 DOI: 10.1021/cn2000124] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Accepted: 03/10/2011] [Indexed: 11/30/2022] Open
Abstract
This Review summarizes the medicinal chemistry found in publications on both orthosteric and allosteric modulators of the metabotropic glutamate receptor 1 (mGlu(1)) from 2005 to the present. The time period covered by the scope of this current review has been particularly rich in mGlu(1)-related publications with numbers quadrupling when compared to the preceding five year period of 2000-2005. Publications in the field peaked in 2007 with over 35 articles appearing in the peer reviewed literature in the course of that year. Given that glutamate is one of the primary excitatory neurotransmitters in the mammalian central nervous system (CNS), it is unsurprising that it acts upon several receptors that are considered to be of potential therapeutic interest for many indications. Orthosteric and allosteric modulation of the receptor is possible, with a logical extrapolation to the chemotypes used for each strategy. The last five years of publications have yielded many mGlu(1) selective antagonist chemotypyes, most of which have shown efficacy in pain in vivo models. However, the primary impact of these compounds has been to highlight the mechanistic safety risks of mGlu(1) antagonism, independent of chemotype. As a review in medicinal chemistry, the primary focus of this paper will be on the design and, to a lesser degree, synthetic strategies for the delivery of subtype selective, CNS penetrant, druglike compounds through a "medchem" program, targeting modulators of the mGlu(1) receptor.
Collapse
Affiliation(s)
- Dafydd R. Owen
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
| |
Collapse
|
9
|
Urwyler S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol Rev 2011; 63:59-126. [PMID: 21228259 DOI: 10.1124/pr.109.002501] [Citation(s) in RCA: 164] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Allosteric receptor modulation is an attractive concept in drug targeting because it offers important potential advantages over conventional orthosteric agonism or antagonism. Allosteric ligands modulate receptor function by binding to a site distinct from the recognition site for the endogenous agonist. They often have no effect on their own and therefore act only in conjunction with physiological receptor activation. This article reviews the current status of allosteric modulation at family C G-protein coupled receptors in the light of their specific structural features on the one hand and current concepts in receptor theory on the other hand. Family C G-protein-coupled receptors are characterized by a large extracellular domain containing the orthosteric agonist binding site known as the "venus flytrap module" because of its bilobal structure and the dynamics of its activation mechanism. Mutational analysis and chimeric constructs have revealed that allosteric modulators of the calcium-sensing, metabotropic glutamate and GABA(B) receptors bind to the seven transmembrane domain, through which they modify signal transduction after receptor activation. This is in contrast to taste-enhancing molecules, which bind to different parts of sweet and umami receptors. The complexity of interactions between orthosteric and allosteric ligands is revealed by a number of adequate biochemical and electrophysiological assay systems. Many allosteric family C GPCR modulators show in vivo efficacy in behavioral models for a variety of clinical indications. The positive allosteric calcium sensing receptor modulator cinacalcet is the first drug of this type to enter the market and therefore provides proof of principle in humans.
Collapse
Affiliation(s)
- Stephan Urwyler
- Department of Chemistry and Biochemistry, University of Berne, P/A Weissensteinweg 3, CH-3303 Jegenstorf, Berne, Switzerland.
| |
Collapse
|
10
|
Sasikumar T, Qiang L, Burnett DA, Greenlee WJ, Li C, Grilli M, Bertorelli R, Lozza G, Reggiani A. A-ring modifications on the triazafluorenone core structure and their mGluR1 antagonist properties. Bioorg Med Chem Lett 2010; 20:2474-7. [DOI: 10.1016/j.bmcl.2010.03.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2010] [Revised: 02/26/2010] [Accepted: 03/01/2010] [Indexed: 10/19/2022]
|
11
|
van Hoorn WP, Bell AS. Searching Chemical Space with the Bayesian Idea Generator. J Chem Inf Model 2009; 49:2211-20. [DOI: 10.1021/ci900072g] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Willem P. van Hoorn
- Department of Chemistry, Pfizer Global Research and Development, Sandwich Laboratories, Sandwich, Kent CT13 9NJ, United Kingdom
| | - Andrew S. Bell
- Department of Chemistry, Pfizer Global Research and Development, Sandwich Laboratories, Sandwich, Kent CT13 9NJ, United Kingdom
| |
Collapse
|
12
|
Mantell SJ, Gibson KR, Osborne SA, Maw GN, Rees H, Dodd PG, Greener B, Harbottle GW, Million WA, Poinsard C, England S, Carnell P, Betts AM, Monhemius R, Prime RL. In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett 2009; 19:2190-4. [DOI: 10.1016/j.bmcl.2009.02.106] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2008] [Revised: 02/26/2009] [Accepted: 02/26/2009] [Indexed: 01/16/2023]
|
13
|
Dolle RE, Bourdonnec BL, Goodman AJ, Morales GA, Thomas CJ, Zhang W. Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2007. ACTA ACUST UNITED AC 2008; 10:753-802. [PMID: 18991466 DOI: 10.1021/cc800119z] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Roland E. Dolle
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Bertrand Le Bourdonnec
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Allan J. Goodman
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Guillermo A. Morales
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Craig J. Thomas
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Wei Zhang
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| |
Collapse
|
14
|
Ito S, Satoh A, Nagatomi Y, Hirata Y, Suzuki G, Kimura T, Satow A, Maehara S, Hikichi H, Hata M, Kawamoto H, Ohta H. Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist. Bioorg Med Chem 2008; 16:9817-29. [DOI: 10.1016/j.bmc.2008.09.060] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2008] [Revised: 09/24/2008] [Accepted: 09/25/2008] [Indexed: 11/16/2022]
|